SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-009162
Filing Date
2023-03-22
Accepted
2023-03-22 16:04:20
Documents
14
Period of Report
2023-03-22
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rani-20230322.htm   iXBRL 8-K 56368
2 EX-99.1 rani-ex99_1.htm EX-99 308647
3 GRAPHIC img125106939_0.jpg GRAPHIC 30251
  Complete submission text file 0000950170-23-009162.txt   542413

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rani-20230322_lab.xml EX-101.LAB 14018
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rani-20230322_pre.xml EX-101.PRE 10303
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rani-20230322.xsd EX-101.SCH 2493
8 EXTRACTED XBRL INSTANCE DOCUMENT rani-20230322_htm.xml XML 4939
Mailing Address 2051 RINGWOOD AVENUE SAN JOSE CA 95131
Business Address 2051 RINGWOOD AVENUE SAN JOSE CA 95131 (408) 457-3700
Rani Therapeutics Holdings, Inc. (Filer) CIK: 0001856725 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40672 | Film No.: 23752915
SIC: 2834 Pharmaceutical Preparations